# Satsuma (STSA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/STSA
## Company Profile
- Ticker: STSA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
Satsuma Pharmaceuticals was a migraine and CNS company focused on acute treatment delivery before its acquisition and restructuring. Its story centered on using inhaled delivery for migraine therapy.
## Why The Stock Is Moving

Current closing-price context is not available for STSA.

## Geographic Base

Headquartered in the United States and listed on NASDAQ before acquisition, Satsuma sat in specialty biotechnology.

## Business Model

The company depended on clinical validation, delivery technology, and the commercial opportunity in migraine care.

## Landscape Position

Satsuma is best treated as a historical CNS and specialty-pharma case rather than a live catalyst name.

## Future Catalysts

- Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled. The market is no longer treating it like a fresh standalone growth story.

## Recent News
- 2026-06-04 12:00 EST — [Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-presentation-of-two-clinical-program-abstracts-at-the-american-headache-society-s-68th-annual-scientific-meeting) — Source: Satsuma
- 2025-11-05 13:00 EST — [Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumitm-in-headache) — Source: Satsuma
- 2025-06-19 13:00 EST — [Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-society-s-67th-annual-scientific-meeting) — Source: Satsuma
- 2025-05-01 00:00 EST — [Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-u-s-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine) — Source: Satsuma
- 2024-11-26 14:00 EST — [Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura) — Source: Satsuma